Aignostics wins €1.4 million ProFIT Funding

EU KoFinanziert

March 6, 2023

Aignostics announces today that they have been awarded a 3 year grant under the ProFIT funding initiative. The ProFit grant was approved by the Investitionsbank Berlin (IBB) and will be used to fund a project focused on product development. The goal of the project will be to realize an AI-powered medical product to improve patient management for lung cancer patients.

ProFIT is an initiative led by the Berlin Senate Department for Economics, Technology and Research and implemented by the Investitionsbank Berlin (IBB). The programme was created for the funding and promotion of research, innovation and technology. The programme has a particular focus on aiding the advancement of new technologies within start-ups and small and medium sized enterprises (SMEs).

The ProFIT programme is designed to offer funding opportunities for support at all points throughout the innovation, technology transfer and product development processes. The ProFIT funding programme is co-financed by the European Union under the EU Regional Development Fund (ERDF).

About Aignostics

Aignostics is a spin-off from Charité – Universitätsmedizin Berlin, and a global leader in the development of AI-powered precision diagnostics for pathology. Started in 2018, Aignostics has 75+ employees in Germany and the US, and is primarily active in pre-clinical, translational, and clinical research with globally leading pharma and biotech clients.

Aignostics GmbH
Viktor Matyas, CEO